Mustang Bio - MBIO Stock Forecast, Price & News

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Analysts Set New Price Targets

MBIO has been the topic of several research reports. B. Riley reduced their price target on shares of Mustang Bio from $5.00 to $4.00 in a research report on Thursday, July 14th. HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Mustang Bio in a report on Friday, May 20th.

Mustang Bio Trading Up 1.6 %

Shares of NASDAQ:MBIO traded up $0.01 during trading hours on Friday, hitting $0.75. 667,729 shares of the company traded hands, compared to its average volume of 890,638. The company's 50 day moving average price is $0.64 and its 200 day moving average price is $0.79. Mustang Bio has a 12 month low of $0.51 and a 12 month high of $3.09. The company has a debt-to-equity ratio of 0.28, a quick ratio of 11.51 and a current ratio of 11.51.

Mustang Bio (NASDAQ:MBIO - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Sell-side analysts expect that Mustang Bio will post -0.85 earnings per share for the current year.